Efficacy and Safety of Biosimilar CT-P47 Versus Reference Tocilizumab: 1-Year Results of a Randomised, Active-Controlled, Double-Blind, Phase III Study in Patients with Rheumatoid Arthritis - Burmester, Gerd; Trefler, Jakub; Racewicz, Artur; Jaworski, Janusz; Zielińska, Agnieszka; Krogulec, Marek; Jeka, Sławomir; Wojciechowski, Rafał; Kolossa, Katarzyna; Dudek, Anna; Krajewska-Włodarczyk, Magdalena; Hrycaj, Paweł; et al. (Clinical drug investigation, 2025)
Keywords: Adolescent; Adult; Aged; Antibodies; Antibodies, Monoclonal, Humanized - administration & dosage; Antibodies, Monoclonal, Humanized - adverse effects; Antibodies, Monoclonal, Humanized - pharmacokinetics; Antibodies, Monoclonal, Humanized - therapeutic use; Antirheumatic Agents - administration & dosage; Antirheumatic Agents - adverse effects; Antirheumatic Agents - pharmacokinetics; Antirheumatic Agents - therapeutic use; Arthritis, Rheumatoid - drug therapy; Biological products; Biosimilar Pharmaceuticals - administration & dosage; Biosimilar Pharmaceuticals - adverse effects; Biosimilar Pharmaceuticals - pharmacokinetics; Biosimilar Pharmaceuticals - therapeutic use; Boolean; Disease; Double-Blind Method; Drug dosages; FDA approval; Female; Humans; Male; Middle Aged; Original; Pharmacokinetics; Remission (Medicine); Rheumatoid arthritis; Treatment Outcome; Young Adult; Poland; United States--US